PILL.CN - Canntab Therapeutics Limited
| Previous Close | 0.4350 |
| Open | 0.4300 |
| Bid | 0.4400 x 0 |
| Ask | 0.4700 x 0 |
| Day's Range | 0.4200 - 0.4550 |
| 52 Week Range | 0.4000 - 1.8400 |
| Volume | 15,200 |
| Avg. Volume | 19,405 |
| Market Cap | 11.135M |
| Beta (3Y Monthly) | -1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0970 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2016-03-08 |
| 1y Target Est | N/A |
- CNW Group
Canntab to utilize the advanced BOSS extraction system from Word Class Extractions to further its own extraction capabilities
TORONTO, Oct. 8, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, today announced the signing of a binding Letter of Intent ("LOI") to establish a joint venture (the "Joint Venture") with World Class Extractions Inc. (CSE:PUMP) ("WCE"). Pursuant to the terms of the LOI, WCE will install certain extraction and processing systems (the "Systems") at Canntab's production facility in Markham, Ontario (the "Facility"). As a late stage applicant, Health Canada approval under the Cannabis Act is at an advanced stage, which, once obtained, will allow Canntab to process high quality cannabis derivatives at the Facility.
- Newsfile
InvestmentPitch Media Video Discusses Canntab's Receipt of Initial Indication of Patentability for Immediate Release Cannabidiol Formulation - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation. The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only patentable but also ...
- CNW Group
Canntab Receives Initial Indication of Patentability for Immediate Release Cannabidiol Formulation
TORONTO, Aug. 15, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it has received an initial assessment from the Geneva-based International Preliminary Report on Patentability ("IPRP") for its Immediate Release Cannabidiol Formulation (the "Immediate Release Formulation"). The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab's formulation is not only patentable but also novel, non-obvious and useful.
- Newsfile
InvestmentPitch Media Video Discusses Canntab's Update of Significant Developments Including Hemp Cultivation and Gel Capsule Manufacturing - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - August 1, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has updated investors about significant developments. Canntab, with headquarters and R & D located in Markham, currently operates out of Cobourg, Ontario where the company has co-location and profit sharing agreements with its strategic partner, FSD Pharma Inc. (CSE:HUGE), a holder of both ...
- CNW Group
Canntab provides corporate update
Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg, leading to a Health Canada request for authorization to begin full scale production and sale. Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status. A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada.
- ACCESSWIRE
Marijuana Investor Magazine June/July 2019 Issue Now Available
ATLANTA, GA / ACCESSWIRE / June 24, 2019 / CannaInvestor Magazine, the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced today ...
- ACCESSWIRE
Canntab Therapeutics Featured in the Canadian Cannabis Investor Magazine
TORONTO, ON / ACCESSWIRE / June 24, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA:TBF1.F) (the " Company " or " Canntab "), the leading innovator in hard pill ...
- Newsfile
InvestmentPitch Media Video Discusses Canntab's Term Sheet with Heritage Cannabis to Process Hemp into High Quality CBD Oil for Canntab's Gelcaps - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has signed a term sheet with Heritage Cannabis Holdings. Under the Term Sheet, Canntab will provide hemp to Purefarma Solutions, a subsidiary of Heritage Cannabis Holdings, for the purpose of processing the hemp into high quality CBD oil. Canntab will transform the resulting oil ...
- ACCESSWIRE
Canntab Therapeutics to Present at the 9th Annual LD Micro Invitational
LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQX: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5th at 11:20AM PST / 2:20PM EST. Richard Goldstein, co-founder and Chief Executive Officer of Canntab Therapeutics will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges" stated Chris Lahiji, while waiting in the longest TSA line in history.
- Business Wire
Canntab Signs Term Sheet with Heritage for Processing Hemp for Sale of CBD Filled Gelcaps
Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.
- CNW Group
Canntab signs term sheet with Heritage for processing hemp for sale of CBD filled gelcaps
TORONTO, May 30, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQX:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) ("Heritage") for the purpose of capsule manufacturing (the "Term Sheet"). Under the Term Sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions ("Purefarma") for the purpose of processing that hemp into high quality CBD oil.
- Newsfile
InvestmentPitch Media Video Discusses Canntab's Receipt of Cultivation Licence from Health Canada to Grow Industrial Hemp - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, has received a cultivation licence from Health Canada to grow industrial hemp. Canntab intends to utilize the Hemp License to grow and cultivate its own supply of hemp biomass for the extraction of CBD and for the purpose of identifying high CBD strains ...
- CNW Group
Canntab Receives Cultivation Licence for Industrial Hemp
Additionally, Canntab's application is currently "In Progress" to obtain a Cannabis Licence (Processing- Standard, Federal Sales - Medical) from Health Canada at its Markham, Ontario facility. TORONTO, May 21, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQX:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has received a cultivation licence for industrial hemp from Health Canada pursuant to the Cannabis Act (Canada) (the "Hemp Licence"). Canntab intends to utilize the Hemp License to secure a substantial amount of hemp biomass that it will grow and cultivate for the extraction of cannabidiol ("CBD") and to conduct research on high CBD hemp varieties, complementing the Company's business plan to also manufacture CBD gel capsules for distribution through its partners in Canada, Australia and Mexico.
- CNW Group
Canntab Therapeutics Now Trading on the OTCQX Best Market
"Historically, it's been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX Best Market. "Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary processes," says Jeff Renwick, co-founder and Chief Executive Officer of Canntab. Canntab is well positioned in the emerging medical cannabis market with 13 patents pending in the United States and Canada covering a range of proprietary processes and formulations.
- Newsfile
InvestmentPitch Media Video Discusses Canntab Approaching Revenue under FSD Pharma's New "Sale for Medical Purposes" Cannabis License - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has advanced its revenue model following FSD Pharma's receipt of a "Sale for Medical Purposes" license. By virtue of Canntab's collaboration and profit sharing agreement with FSD Pharma (CSE:HUGE), this new license allows Canntab to produce ...
- CNW Group
Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada
TORONTO, April 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab") is pleased to announce that by virtue of FSD Pharma Inc. ("FSD"), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a "sale for medical purposes" licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the "FSD Licence"), Canntab is close to being in a position to sell its products and generate revenue. The FSD Licence allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD's Health Canada approved facility in Cobourg, Ontario.
- Newsfile
FSD Pharma Receives Cannabis Sales License from Health Canada
\- New license positions FSD to serve the growing medicinal use markets - Toronto, Ontario--(Newsfile Corp. - April 22, 2019) - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went into effect on April 18, 2019.The license allows the current FSD facility ...
- GlobeNewswire
Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services
Canntab Therapeutics Limited (CSE:PILL) (the “Company” or “Canntab”) is pleased to announce that, effective March 21, 2019, it has engaged Relations Publiques Paradox Inc. (“Paradox”) to provide investor relations services to the Company. Paradox is a Montreal based investor relations consultancy firm that has been in business for 20 years, and is led by entrepreneur, Jean-Francois Meilleur. Paradox has represented a number of public companies through its extensive network and experience in the capital markets.
- GlobeNewswire
Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD $5.0 million of the Supplier’s hemp crop for a period of 5 years commencing in 2019 at a purchase price of CAD $100.0 per kg per 1% of CBD extracted from the flower.
- GlobeNewswire
Canntab Provides Corporate Update
Moving into FSD Pharma and FSD Processing LicenseMackie Research ExtensionDirector Estate Planning InitiativeOTCQB under symbol CTABF TORONTO, Feb. 19, 2019 -- Canntab.
- GlobeNewswire
Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules, announced today that it has entered into a supply agreement (the “Agreement”) with FSD Pharma Inc. (“FSD Pharma”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.
- GlobeNewswire
FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media
SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.
- GlobeNewswire
Canntab & FSD Pharma Make Cannabis More Palatable for Doctors -- CFN Media
SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.
- GlobeNewswire
Canntab Partners with Leading Surgeon to Conduct Pain Management Trial -- CFN Media
SEATTLE, Dec. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F), The company recently announced a partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, MD, to conduct a clinical trial to analyze the efficacy of cannabis as a replacement for opioids in postoperative care. The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain.
- GlobeNewswire
Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets
Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications. The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets. The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.